News

Novel two-biomarker strategy permits early ACS rule-out

View on the News

New assay is a discharge asset

In an era of tight resource utilization, patient throughput problems with ED backlogs, and judicious placement of higher-acuity patients into the hospital, a risk-stratification system for acute coronary syndrome (ACS) that would allow for early discharge from the ED with outpatient follow-up rather than the current practice of an extended ED workup for two troponins 6 hours apart or hospital admission, has the potential to radically change care processes.
Hospitals have developed observation units to address the need to provide less-intensive services in these clinical situations, but these units have faced significant patient concerns due to higher copays for services provided that are billed by outpatient codes.

Dr. Hiren Shah

This study, using the novel biomarker called copeptin in addition to troponin, has shown equivalent 30-day incidence of major cardiovascular events when the early-discharge strategy is compared to current practice. I would note, however, that this assay was utilized only in low- to intermediate-risk patients, and that clinical assessment of cardiovascular risk should always supersede this new assay in the discharge decision-making process. Of course, the challenges in the determination of risk and the variability in individual physician clinical risk-assessment approaches remain significant barriers no matter which assay system is used.

Future larger studies and those with a lower lost-to-follow-up rate than the current one will yield important results that may better evaluate the copeptin assay. If the results are similar in a more thorough study, the potential to change clinical practice for our ACS patients and to affect hospital resource utilization remains very significant.

Dr. Hiren Shah is an assistant professor of medicine in the Feinberg School of Medicine, Northwestern University, Chicago, and a medical director of the Medicine and Cardiac Telemetry Hospitalist Unit at Northwestern Memorial Hospital. He is on the advisory board of Hospitalist News.


 

AT THE ESC CONGRESS 2013

BiC-8 coinvestigator Dr. Kurt Huber said in an interview that the dual-biomarker early rule-out strategy is now used routinely in the hospital where he practices. Yet like Dr. Arnett, he considers a confirmatory test "extremely important" before concluding that the strategy is ready for prime-time use in every ED.

"The most important message from BiC-8, I think, is that these were patients at low to intermediate risk; they’re not the high-risk patients. And it’s also important that the physician doesn’t rely only on the test result, but also takes a final look at the clinical situation before releasing the patient. There is some overruling when patients are biomarker-negative but have typical risk markers. No test is 100% accurate. Clinical judgment remains extremely important," emphasized Dr. Huber, professor and director of cardiology and emergency medicine at Wilhelminen Hospital, Vienna.

The BiC-8 trial was sponsored by ThermoFisher Scientific and six university medical centers in German-speaking Europe. Dr. Moeckel reported receiving a research grant from ThermoFisher and serving as a consultant to Bayer, AstraZeneca, and The Medicines Company. Dr. Arnett and Dr. Huber had no conflicts of interest to declare.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

One-year outcomes support emergency department CCTA
MDedge Emergency Medicine
STREAM trial endorses fibrinolysis-first in selected STEMIs
MDedge Emergency Medicine
High-sensitivity troponin T assay shows prognostic superiority
MDedge Emergency Medicine
Swedish NSTEMI registry suggests comparability of heparin, bivalirudin
MDedge Emergency Medicine
Vitamin C protects kidneys against angiography contrast
MDedge Emergency Medicine
PCI in noninfarct coronaries helps STEMI patients
MDedge Emergency Medicine
Prasugrel pretreatment ups bleeding risk in NSTE ACS
MDedge Emergency Medicine
TASTE: Thrombus aspiration has no mortality benefit in STEMI
MDedge Emergency Medicine
Risk of stopping dual-antiplatelet therapy after stenting depends upon the reason
MDedge Emergency Medicine
Gender-specific biomarker thresholds urged in MI diagnosis
MDedge Emergency Medicine